BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Workshop on ECG interpretation also marks launch of “Handbook on ECGs – Volume 2”
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
